Presentation and outcome of myocardial infarction with non-obstructive coronary arteries in coronavirus disease 2019

Kevin John, Amos Lal, Nitish Sharma, Amr ElMeligy, Ajay K Mishra

Abstract
Among the cardiac complications of coronavirus disease 2019 (COVID-19), one increasingly reported in the literature is myocardial infarction with non-obstructive coronaries (MINOCA). We reviewed all reported cases of MINOCA in COVID-19 patients to summarize its clinical features, evaluation, and treatment. We performed a literature search in Pubmed using the search terms ‘COVID-19’ and ‘MINOCA’ or ‘non-obstructive coronaries’. Among the reported cases, the mean age was 61.5 years (SD ± 13.4), and 50% were men. Chest pain was the presenting symptom in five patients (62.5%), and hypertension was the most common comorbidty (62.5%). ST-elevation was seen in most patients (87.5%), and the overall mortality rate was 37.5%. MINOCA in COVID-19 is an entity with a broad differential diagnosis. Therefore, a uniform algorithm is needed in its evaluation to ensure timely diagnosis and management.

Key Words: COVID-19; Myocardial infarction with non-obstructive coronary arteries; Outcome
Core Tip: Myocardial infarction with non-obstructive coronary arteries (MINOCA) may be more commonly seen in patients with coronavirus disease 2019 (COVID-19). To ensure that cases of MINOCA are identified and managed appropriately, a well-defined, algorithmic approach should be taken while evaluating COVID-19 patients with evidence of myocardial injury. This review summarizes the clinical characteristics and outcomes of all COVID-19 patients with MINOCA reported to date.

Citation: John K, Lal A, Sharma N, ElMeligy A, Mishra AK. Presentation and outcome of myocardial infarction with non-obstructive coronary arteries in coronavirus disease 2019. World J Crit Care Med 2022; 11(3): 129-138
URL: https://www.wjgnet.com/2220-3141/full/v11/i3/129.htm
DOI: https://dx.doi.org/10.5492/wjccm.v11.i3.129

INTRODUCTION

Myocardial infarction with non-obstructive coronaries (MINOCA) is defined as a rise or fall of cardiac troponin, with at least one value above the 99th percentile of the upper reference limit, corroborative clinical evidence of infarction (classic symptoms, electrocardiogram changes, or new wall motion abnormality), non-obstructive coronary arteries on angiography (< 50% obstruction), and lack of an alternative diagnosis[1]. MINOCA is seen in 5%-6% of patients with acute myocardial infarction (AMI)[2]. However, this number may be as high as 15% in certain subgroups[2]. Compared to patients with AMI due to obstructive coronary artery disease (CAD), patients with MINOCA are younger, consist of more women, and have a lesser prevalence of traditional risk factors such as dyslipidemia, diabetes mellitus, hypertension, tobacco use, and family history of AMI[1].

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to more than 4,250,000 deaths worldwide. Although primarily a respiratory illness, it is becoming increasingly clear that COVID-19 is a multi-system disease. How COVID-19 affects the cardiac system has been well documented. However, as more cases are reported, uncommon presentations and complications of COVID-19 are surfacing. Although there have been many reports of MINOCA in COVID-19 patients, a unified approach to evaluate such patients is lacking. In this paper, we review cases of MINOCA reported in patients with COVID-19 and provide a summary of its clinical features, evaluation, and treatment.

METHODS

In this review, we included articles on COVID-19 and MINOCA published in PubMed until January 2022. We used the search terms ‘COVID-19’ and ‘MINOCA’ or ‘non-obstructive coronaries’. Case reports, case series, retrospective, and prospective observational studies on adult patients with COVID-19 were eligible to be included. We excluded opinions, recommendations, and reviews that did not have clinical details of patients. Patients whose initial diagnosis of MINOCA was modified after further evaluation were also excluded. Studies in languages other than English were translated using Google Translate. Two independent clinicians were involved in the screening of the articles.

RESULTS

We found five cases and one case series of three patients with MINOCA and COVID-19[3-8] (Table 1). We also found five observational studies of MINOCA in COVID-19 patients, which are discussed separately[9-13] (Table 2). Among the reported cases, the mean age of patients was 61.5 years (SD ± 13.4), and 50% were men.

Demographic details and presentations

Chest pain was the presenting symptom in five patients (62.5%), two patients (25%) had dyspnea without chest pain, and one patient (12.5%) was found unresponsive at the time of presentation. Hypertension was the most common comorbidity and was present in 62.5% of the patients. Other comorbidities included diabetes mellitus, chronic obstructive pulmonary disease, non-ischemic heart failure with reduced ejection fraction, past ST-elevation myocardial infarction (STEMI), hypercholesterolemia, and motor-neuron disease.
| Sl. No | Ref. | Age in yr | Sex | Presenting complaint                  | Comorbidities | Chest imaging | ECG              | Cardiac troponins | Echocardiogram | Angiogram | Other investigations                                                                 | Management                                      | Outcome                                                                 |
|-------|------|-----------|-----|--------------------------------------|---------------|----------------|------------------|------------------|----------------|-----------|-------------------------------------------------------------------------------------|------------------------------------------------|----------------------------------------------------------------------|
| 1     | [3]  | 47        | M   | Shortness of breath for 6d, angina on day 2 of admission | Hypertension  | CT thorax: Diffuse bilateral infiltrates, ground glass opacities, crazy paving with thickened interlobular septa, and consolidation in lower lobes | Inferior STEMI  | 0.012 ng/mL (Ref range: <0.026 ng/mL) | Not reported | Emergency coronary angiography showed 30%-40% stenosis in the midportion of the left anterior descending artery. In addition to this, the left main coronary artery, left circumflex artery and right coronary artery were normal. ST segment elevation regressed in the ECG of the patient, who had no more ischemic cardiac symptoms after the intervention | Emergency coronary angiography showed 30%-40% stenosis in the midportion of the left anterior descending artery. In addition to this, the left main coronary artery, left circumflex artery and right coronary artery were normal. ST segment elevation regressed in the ECG of the patient, who had no more ischemic cardiac symptoms after the intervention | CTPA did not reveal any evidence of pulmonary embolism. Cardiogoniometry (a non-invasive medical tool worked with spatiotemporal vectocardiographic advancement), was performed after 24 h of the pain, it revealed septal inferior myocardial ischemia | Discharged on the eleventh day of his hospitalization in a healthy state |
| 2     | [4]  | 48        | F   | Pain in her chest and left shoulder for 1 day | none          | Inverted T-waves in II, III, aVF, V4, V5, and V6 | Upward of 25000 pg/mL (Ref range: 0.0-51.4 pg/mL) | Hypokinesis in the apical inferior segment of the left ventricle | CTCA was performed to exclude a coronary origin for the complaints and for the laboratory and ECG abnormalities, which revealed no significant coronary obstruction | CMR showed features of myocardial oedema restricted to the mid-ventricular to apical territory of the right coronary artery (RCA). Based on subendocardial to partially transmural late gadolinium enhancement in the mid-ventricular to apical inferior wall, an acute myocardial infarction was diagnosed. Cardiac positron emission tomography–computed tomography showed evidence of reduced metabolic activity in the area affected by the infarction | Acetylsalicylic acid, prophylactic-dose low-molecular-weight heparin, and statin. Later dual anti-platelet therapy and an angiotensin-converting-enzyme inhibitor was started | Discharged. Follow-up echocardiography 2 d after discharge revealed a normal ejection fraction (58%) despite persistent inferior apical akinesia |
| 3     | [5]  | 86        | M   | Cough and shortness of breath which progressed | none          | Chest X-ray: bilateral infiltrates at the bases with no 3–4 mm ST-segment elevations in leads V2 and V3 | 4.82 ng/mL (Ref range: < 0.10) | Ejection fraction of 50%-55%, no significant regional wall motion | No significant coronary artery disease | Admitted to the intensive care unit, requiring mechanical ventilation and Respiratory status worsened and he required increased oxygen and positive | | | |
| No | [6] | Age | Sex | Presenting Symptoms | Comorbidities | Laboratory Findings | Imaging Findings | Cardiac Findings | Treatment | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| 4 | 61 M | Shortness of breath, respiratory failure requiring intubation | Hypertension, diabetes mellitus | | 2 mm of antero-lateral ST-elevation without reciprocal depression | | Moderate left ventricular systolic dysfunction | | Loading dose of ticagrelor and IV heparin | Died on day 8 |
| 5 | 59 F | Found minimally responsive on the ground. Intubated by paramedics | Hypertension, COPD | | ST-segment elevations in V1–V4 and reciprocal ST-depressions in leads II, III, and aVF | | Reduced left ventricular ejection fraction of 40% with antero-apical wall hypokinesis | | Not specified | Extubated on Day 3. Discharged home subsequently |
| 6 | 69 F | Acute onset chest tightness and dyspnea | Non-ischemic heart failure with reduced ejection. Implantable cardioverter-defibrillator was placed in 2004. Motor neuron disease, diagnosed 4 yr previously | | Left bundle branch block. On day 3 progressive dynamic concordant ST-elevation in V1–V2 and ST-depression in V3-V5 | | Impaired left ventricular function which was similar to baseline | | Loading dose dual antiplatelets, therapeutic low molecular weight heparin, high-dose IV diuretics, and IV nitrates | The patient died on Day 7 of admission |
| 7 | 51 M | Left sided chest pain, diaphoresis, syncope | Hypertension and hypercholesterolemia | | 3.5 mm ST elevation in I and aVL, 5 mm isolated ST elevation in lead V2, with deep reciprocal depressions in III, aVF and aR | | Not reported | | Admitted to Cardiac Intensive Care Unit and started on supportive measures. Treated with lopinavir/ritonavir 400 mg/100 mg tablet every 12 h for 4 d and hydroxychloroquine 500 mg every 12 h, then hydroxy- | The patient recovered and was discharged home on day 26 on aspirin, statin and metoprolol |
pleural effusions, interpreted as consistent with congestive heart failure

| 8 | [8] | 71 F | Chest-pain | Hypertension, past STEMI | Chest X-ray: No pulmonary opacities | ST-segment elevation in inferior leads, and ST depression, and inverted T waves in V1-3 | Negative | Preserved left ventricular ejection fraction of 50% with inferior and septal hypokinesis | Non-obstructive coronary artery disease | Loading dose of ticagrelor and unfractionated heparin | Discharged |

chloroquine alone 400 mg daily

Investigations

ST-elevation was seen in most patients (87.5%), while one patient (12.5%) had only T-wave inversion. In addition, a new-onset left bundle branch block was seen in one patient (12.5%)[6]. Three-quarters of all patients had elevated troponin levels. On echocardiography, three patients (37.5%) had reduced ejection fraction, and four (50%) had preserved ejection fraction. One case report did not include echocardiography findings. Non-obstructive coronary arteries were demonstrated by invasive angiography in all patients, except one who underwent computed tomography coronary angiography (CTCA)[4]. Cardiac magnetic resonance imaging (CMR) was performed on one patient. It showed myocardial edema restricted to the mid-ventricular to apical territory of the right coronary artery, and subendocardial-to-partially transmural late gadolinium enhancement in the mid-ventricular to apical inferior wall. These findings were suggestive of acute myocardial infarction[4]. The same patient underwent cardiac positron emission tomography-computed tomography (PET-CT), which showed reduced metabolic activity in the area affected by the infarction. Another patient underwent computed tomographic pulmonary angiography, which ruled out pulmonary embolism, and cardiogoniometry, which revealed septal inferior myocardial ischemia[3].

Treatment and outcome

While most patients were treated with supportive care, antiplatelets, statins, and anticoagulation, one patient received anti-viral therapy (lopinavir/ritonavir) with hydroxychloroquine[7]. The overall mortality rate was 37.5%.

Observational studies reporting outcomes of MINOCA in COVID-19

In the five observational studies included in this review, the incidence of MINOCA among COVID-19 patients with an acute coronary syndrome varied from 5.2% to 54.5%[9-13]. Demographic details were only reported in the study by Stefanini et al[9]. The mean age of patients with MINOCA in that study was 69.27 years (SD ± 10.6), and 54.5% were male. Hypertension was the most common comorbidity.
MINOCA: Myocardial infarction with non-obstructive coronary arteries; MI: Myocardial infarction; LVEF: Left ventricular ejection fraction; EKG: Electrocardiogram; LBBB: Left bundle branch block; RWMA: Regional Wall Motion Abnormality; ECHO: Echocardiography.

(91.8%), followed by chronic kidney disease (45.4%), dyslipidemia (27.3%) and diabetes mellitus (9.1%). The proportion of patients with ST-elevation on ECG was between 81.8% and 100%, and the mortality rate ranged from 45.4% to 66%.

**DISCUSSION**

Gross and Sternberg first described MINOCA in 1939[14]. Later, the term MINC or MINCA (myocardial infarction with normal coronary arteries) was coined, which was modified to MINOCA to be more inclusive. Other words that have been used in the literature to describe this pathology include ‘acute coronary syndromes with normal or near-normal coronary arteries’ (ACS-NNOCA) and ischemic syndromes with non-obstructive coronaries (INOCA). Strictly speaking, MINOCA is a subset of MINOCA, which is a subset of ACS-NNOCA. The subtle differences between these terms have been confusing as these terms are often used interchangeably. Nevertheless, the term MINOCA provides a framework for evaluating such patients and is often used as a ‘working diagnosis’. Further evaluation may reveal secondary causes such as myocarditis, Takotsubo cardiomyopathy, sepsis, cardiac contusion, spontaneous coronary artery dissection, microvascular disease, coronary artery spasm, or missed obstructive coronary artery disease. If a secondary cause is not found, a diagnosis of ‘unclassified MINOCA’ is made[1].

The proportion of MINOCA seems to be higher in COVID-19 patients. In the study by Popovic et al [10], there was a statistically significant increase in the proportion of MINOCA in COVID-19 patients compared to a historical cohort (54.5% vs 1.4%, P < 0.001). Due to the heterogeneity in case definitions and evaluation protocols between centers, the actual proportion of MINOCA among COVID-19 patients is difficult to estimate. One can gauge the upper limit of this estimate from the proportion of COVID-19 patients with acute cardiac injury (ACI), which is one of the earliest measures of cardiac involvement reported during the COVID-19 pandemic. ACI, defined as cardiac-troponin elevation with values exceeding the 99th percentile of the upper reference limit, was observed in 8%-62% of COVID-19 patients [15]. Also noteworthy was that any amount of cardiac injury was significantly associated with mortality (adjusted HR 1.75, P < 0.001)[16].

Some other characteristics of COVID-19 patients with MINOCA can be extrapolated from the results of a systematic review of 161 patients from 42 studies of COVID-19 patients with ST-elevation[17]. The authors observed that patients with non-obstructive CAD had more diffuse ST-segment elevation (13% vs 1%, P = 0.03) and diffuse left ventricular wall-motion abnormality (23% vs 3%, P = 0.02) when compared to those with obstructive CAD[17]. In the same review, the proportion of men in the group with obstructive CAD was higher than in the group with non-obstructive CAD (79% vs 57%) [17].

Our literature review found that many patients with COVID-19 and MINOCA received alternative diagnoses such as Takotsubo cardiomyopathy, coronary vasospasm, myocarditis, and coronary vasculitis on further evaluation. This is consistent with the concept that MINOCA is a dynamic diagnosis, and patients who were initially diagnosed with MINOCA may receive a revised diagnosis on
further evaluation. However, some patients were presumed to have myocarditis without objective evidence for the same[18-21]. A diagnosis of MINOCA or MINOCA under evaluation would better suit such patients. It must also be noted that the cases of MINOCA with COVID-19 that were included in this review are cases of ‘unclassified MINOCA.’

Specific causes for MINOCA in COVID-19 patients

Myocarditis: Myocarditis is defined as an inflammatory disease of the myocardium diagnosed by histological, immunological, immunohistochemical, and molecular criteria[22]. There have only been a handful of COVID-19 patients with endomyocardial biopsy-proven myocarditis[23,24]. Even in these patients, the SARS-CoV-2 genome could not be isolated from the biopsy sample. Thus, there is no conclusive proof that SARS-CoV-2 infects the myocardium resulting in myocarditis. Instead, the mechanism is probably one of immune-mediated damage and would justify steroids for treatment. However, many COVID-19 patients who were diagnosed with myocarditis do not meet the strict diagnostic criteria for the same, and giving steroids to such patients may be harmful[18-21].

Takotsubo cardiomyopathy: Takotsubo cardiomyopathy is an intriguing disorder, and its mechanism is yet to be elucidated fully. Takotsubo cardiomyopathy has been well documented in COVID-19 patients and can be due to the infection or the emotional stress associated with the pandemic[25]. Whether Takotsubo cardiomyopathy should be included as a cause of MINOCA is debatable. This is because the ‘Fourth Universal Definition of Myocardial Infarction’ does not consider Takotsubo cardiomyopathy a form of myocardial infarction[26]. On the other hand, the elevation of cardiac troponins is well documented in Takotsubo cardiomyopathy[27]. In our opinion, Takotsubo cardiomyopathy must be included in the diagnostic algorithm of MINOCA as there seems to be an increased incidence in COVID-19. Such a diagnosis carries certain therapeutic and prognostic implications as well.

Coronary vasculitis: Although coronary vasculitis is a rare cause of MINOCA, it has been reported in patients with COVID-19. Feuchtner et al[27] described an interesting case of a 48-year-old COVID-19 patient who was evaluated for chest pain and was found to have non-obstructive coronaries suggestive of MINOCA. However, further evaluation with CMR confirmed subendocardial inferior zonal late enhancement, and CTCA showed diffuse irregular vessel wall thickening and perivascular edema suggestive of vasculitis. The patient was managed with acetylsalicylic acid and clopidogrel and was discharged after cardiac enzyme levels declined. Postmortem studies showed COVID-19 viral inclusion bodies in endothelial cells, supporting the possibility of endothelial cell infection and endarteritis[28]. Hence, COVID-19 induced coronary vasculitis may be more common than currently reported. This case also underscores the importance of identifying patients with MINOCA and evaluating them further, rather than giving a presumptive diagnosis of myocarditis.

Spontaneous coronary artery dissection: Multiple case reports in COVID-19 patients have documented spontaneous coronary artery dissection[29-32]. The obstruction is caused by the separation of the medial and adventitial walls, with an intramural hematoma protruding into the lumen. It is hypothesized that there is an intrinsic underlying vasculopathy, and the dissection is precipitated by stress, catecholamine surge, physical activity, or sympathetic stimulation[33]. The underlying endothelial dysfunction and thrombo-inflammation may be the reason for coronary artery dissection occurring in COVID-19.

Coronary vasospasm: Diagnosis of coronary vasospasm in COVID-19 patients with MINOCA is challenging, but possible, if a systematic approach is followed. This was demonstrated by Rivero et al [34] in their case report of a 66-year-old man who presented with bilateral COVID-19 pneumonia and chest pain. After angiography, optical coherence tomography showed a stable, mainly fibrotic athemomatous plaque. The diagnosis of coronary vasospasm was clinched by administering intracoronary ergonovine at increasing doses which led to severe chest pain and universal ST-segment elevation. Coronary angiography done at this time revealed nearly occlusive coronary vasospasm involving both the left anterior descending coronary artery and left circumflex coronary artery. Given how challenging it is to diagnose coronary vasospasm, it may be another under-reported cause of MINOCA in COVID-19.

Miscellaneous causes: Type 2 myocardial infarction refers to events that occur due to a mismatch between myocardial oxygen supply and demand[26]. This is a heterogeneous class that can include various causes such as sepsis, anemia, arrhythmia, and pulmonary embolism—all of which can be seen in the setting of COVID-19 infection.

Evaluation of MINOCA

The differential diagnosis for MINOCA is broad, and therefore, a complete history and physical examination must remain at the core of its evaluation. It is also vital to re-take history and re-examine the patient multiple times at various stages of the evaluation process. This will ensure that investigations are directed appropriately and a ‘fishing-expedition’ approach is avoided. The initial set of investigations may give clues to the underlying diagnosis before more invasive tests are undertaken. In a prospective cohort of STEMI patients who underwent primary percutaneous coronary intervention
(PPCI) during the COVID-19 outbreak, patients with COVID-19 and MINOCA had elevated markers of inflammation and abnormal coagulation parameters[10]. Moreover, anti-phospholipid antibodies were observed in three of these patients.

Once obstructive coronary artery disease has been ruled out, the most important investigation for evaluating the cause of MINOCA is CMR[35]. A large prospective multicenter observational study conducted from 2007 to 2011 included 152 patients with MINOCA. In this study, CMR showed that 19% of the patients had signs of myocardial necrosis, 7% had signs of myocarditis, and 7% had unrecognized hypertrophic cardiomyopathy or could not be classified[36]. A meta-analysis of 34 studies with 199 COVID-19 patients for whom CMR was performed showed abnormal results in 79% and myocarditis in 40.2%[37]. A caveat is that the absence of myocardial necrosis on CMR does not exclude MINOCA as they may have other findings that support the diagnosis[38].

Prognosis
While the prognosis of MINOCA depends on the underlying disease, most studies to date indicate a better prognosis for MINOCA when compared to patients with AMI due to obstructive CAD[2]. A review of ST-elevation in COVID-19 patients observed an overall in-hospital mortality of 30%, with no significant difference between obstructive and non-obstructive CAD[17]. This is comparable with the mortality rate of 37.5% in our review. The effect of anti-viral therapy for MINOCA on COVID-19 is debatable. While none of the patients who died received anti-viral therapy, the small sample size and study designs preclude us from drawing definite conclusions[39,40]. As more cases of MINOCA are reported, it may be feasible to conduct well-designed prospective studies to explore these questions further.

LIMITATIONS
There are several limitations to this review. Many cases of MINOCA may have been treated along the lines of COVID-19 associated myocarditis. Therefore, it is likely that MINOCA is grossly under-reported in the literature. The small sample size of this review, due to the under-reporting of cases and the rarity of this condition, limits the generalizability of our findings. The publication of challenging cases with a positive outcome may have led to publication bias. There is also a lack of uniformity in the evaluation and diagnosis of MINOCA in COVID-19[41].

CONCLUSION
This review highlights that MINOCA in COVID-19 has a broad differential diagnosis that must be evaluated with a systematic diagnostic algorithm. COVID-19 patients with MINOCA had a mean age of 61.5 years, and 50% of them were men. The most common presenting symptom was chest pain (62.5%), and ST-elevation was present in most patients (87.5%). The overall mortality rate was 37.5%. More studies are required to arrive at a reliable estimate of the true prevalence and prognostic relevance of MINOCA.

FOOTNOTES
Author contributions: John K and Mishra AK contributed to the conceptual design of the study; John K and Mishra AK independently screened the articles and extracted the data; John K, Mishra AK, and Lal A contributed to the write-up and submission of the study; Mishra AK and Lal A reviewed the final manuscript; All authors reviewed and agreed with the final content of the article.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: United States

ORCID number: Kevin John 0000-0003-3382-0294; Amos Lal 0000-0002-0021-2033; Nitish Sharma 0000-0002-6221-3197; Amr ElMeligy 0000-0002-3053-0024; Ajay K Mishra 0000-0003-4862-5053.

S-Editor: Liu JH
REFERENCES

1 Tamis-Holland JE, Jneid H, Reynolds HR, Agewall S, Brilakis ES, Brown TM, Lerman A, Cushman M, Kumbhani DJ, Arslanian-Engoren C, Bolger AF, Beltrame JF; American Heart Association Interventional Cardiovascular Care Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; and Council on Quality of Care and Outcomes Research. Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association. Circulation 2019; 139: e891-e908 [PMID: 3091389 DOI: 10.1161/CIR.0000000000000670]

2 Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. Circulation 2015; 131: 861-870 [PMID: 25587100 DOI: 10.1161/CIRCULATIONAHA.114.011201]

3 Ergulu SE, Ademoglu E, Bayram S, Aksel G. A Rare Cause of ST-Segment Elevation Myocardial Infarction in COVID-19: MINOCA Syndrome. Medeni Med J 2021; 36: 63-68 [PMID: 33828892 DOI: 10.5222/MMJ.2021.25473]

4 Burkert FR, Niedereiter L, Dichtl W, Mayr A, Virgolini I, Klauser A, Weiss G, Bellmann-Weiler R. Case report of a COVID-19-associated myocardial infarction with no obstructive coronary arteries: the mystery of the phantom embolus or local endothelitis. Eur Heart J Case Rep 2021; 5: ytaa521 [PMID: 33598613 DOI: 10.1093/ehjcr/ytaa521]

5 Meizinger C, Klugherz B. Focal ST-segment elevation without coronary occlusion: myocardial infarction with no obstructive coronary atherosclerosis associated with COVID-19-a case report. Eur Heart J Case Rep 2021; 5: ytaa532 [PMID: 33768195 DOI: 10.1093/ehjcr/ytaa532]

6 Saririan M, Armstrong R, George JC, Olechowski B, O'Connor S, Byrd JB, Chapman AR. ST-segment elevation in patients presenting with COVID-19: case series. Eur Heart J Case Rep 2021; 5: ytaa553 [PMID: 33644657 DOI: 10.1093/ehjcr/ytaa553]

7 Castagna F, Cerrud-Rodriguez R, Villela MA, Bortnick AE. SARS-COV-2 infection presenting as ST-elevation myocardial infarction. Catheter Cardiovasc Interv 2021; 97: E339-E342 [PMID: 32743085 DOI: 10.1002/ccd.28974]

8 Bujak K, Kazik A, Wróbel M, Piega J, Lekston A, Gąsior M. COVID-19 mimicking ST-segment elevation myocardial infarction. Postepy Kardiol Interwencyjnej 2020; 16: 213-215 [DOI: 10.5114/pci.2020.95362]

9 Stefanini GG, Montorfano M, Trabattoni D, Andreini D, Ferrante G, Ancona M, Metra M, Curello S, Maffeo D, Pero G, Cuccuci M, Assanelli E, Bellini B, Russo F, Ielasi A, Trespili M, Danzi GB, Vandoni P, Bollati M, Barbieri L, Oreglia J, Lettieri C, Cremonesi A, Caruso S, Reimers B, Cordorelli G, Chieffo A. ST-Elevation Myocardial Infarction in Patients With COVID-19: Clinical and Angiographic Outcomes. Circulation 2020; 141: 2113-2116 [PMID: 32352308 DOI: 10.1161/CIRCULATIONAHA.120.047525]

10 Popovic B, Varlot J, Metzdorf PA, Jeulin H, Goelbringer F, Camenzind E. Changes in characteristics and management among patients with ST-elevation myocardial infarction due to COVID-19 infection. Catheter Cardiovasc Interv 2021; 97: E319-E326 [PMID: 32667726 DOI: 10.1002/ccd.29114]

11 Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B, Ibrahim H, Friedman GH, Thompson C, Alviar CL, Chadow HL, Fishman GI, Reynolds HR, Keller N, Hochman JS. ST-Segment Elevation in Patients with Covid-19 - A Case Series. N Engl J Med 2020; 382: 2478-2480 [PMID: 32302081 DOI: 10.1056/NEJMoa2009020]

12 Hamadah A, Aldujeli A, Briedji K, Tescan KM, Sànz-Sánchez J, Al Dujelii M, Al-Obeidi A, Díez JL, Žaliūnas R, Stoler RC, McCullough PA. Characteristics and Outcomes in Patients Presenting With COVID-19 and ST-Segment Elevation Myocardial Infarction. Am J Cardiol 2020; 131: 1-6 [PMID: 32732010 DOI: 10.1016/j.amjcard.2020.06.063]

13 Secco GG, Tarantini G, Mazzarotto P, Garbo R, Parisi R, Maggio S, Vercellino M, Pistis G, Audo A, Kozel D, Centini G, Di Mario C. Invasive strategy for COVID patients presenting with acute coronary syndrome: The first multicenter Italian experience. Catheter Cardiovasc Interv 2021; 97: 195-198 [PMID: 32040049 DOI: 10.1002/ccd.28959]

14 Gross H, Sternberg WH. Myocardial Infarction Without Significant Lesions of Coronary Arteries. Arch Intern Med 1939; 64: 249-267. [DOI: 10.1001/archinte.1939.00190020035003]

15 Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. PloS One 2020; 63: 390-391 [PMID: 3169400 DOI: 10.1001/jpcc.2020.03.001]

16 Lala A, Johnson KW, Januzzi JL, Russak AJ, Panarine J, Richter F, Zhao S, Sonani S, Van Vleck T, Vaid A, Chaudhary F, De Freitas JK, Fayad ZA, Pinney SP, Levin M, Charney A, Bagiella E, Narula J, Glicksberg BS, Nadkarni G, Mancini DM, Fuster V, Mount Sinai COVID Informatics Center. Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. J Am Coll Cardiol 2020; 76: 533-546 [PMID: 32517963 DOI: 10.1016/j.jacc.2020.06.007]

17 Diaz-Arocuita C, Torres-Valencia J, Saucedo-Chinchay J, Cuevas C. ST-segment elevation in patients with COVID-19: a systematic review. J Thoromb Thrombolysis 2021; 52: 738-745 [PMID: 33646500 DOI: 10.1007/s11239-021-02411-9]

18 El-Assaad I, Hood-Pishchany MI, Kheir J, Mistry K, Dixit A, Halyabar O, Mah DY, Meyer-Macaulay C, Cheng H. Complete Heart Block, Severe Ventricular Dysfunction, and Myocardial Inflammation in a Child With COVID-19 Infection. JACC Case Rep 2020; 2: 1351-1355 [PMID: 32835278 DOI: 10.1016/j.jaccr.2020.05.023]

19 Khalid Y, Dasu N, Dasu K. A case of novel coronavirus (COVID-19)-induced viral myocarditis mimicking a Takotsubo cardiomyopathy. HeartRhythm Case Rep 2020; 6: 473-476 [PMID: 32817822 DOI: 10.1016/j.hrcr.2020.05.020]

20 Hussain H, Fadel A, Alwaehi H, Guardiola V. Coronavirus (COVID-19) Fulminant Myopericarditis and Acute Respiratory Distress Syndrome (ARDS) in a Middle-Aged Male Patient. Cureus 2020; 12: e8808 [PMID: 32607304 DOI: 10.7559/cureus.8808]

21 Rehem M, Gondal A, Rehman NU. Atypical Manifestation of COVID-19-Induced Myocarditis. Cureus 2020; 12: e8685
John K et al. A review of MINOCA in COVID-19

[PMID: 32577331 DOI: 10.7759/eureus.8685]

22 Caforio AL, Pankweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Heliö T, Heymans S, Jahns R, Klingel K, Linhart A, Mailsch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34: 2636-2648. DOI: 10.1093/eurheartj/ehs210

23 Sala S, Paretto G, Grammegna M, Palmisano A, Villatore A, Vignale D, De Cobelli F, Tresoldi M, Cappelletti AM, Basso C, Godino C, Esposito A. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J 2020; 41: 1861-1862. DOI: 10.1161/euroheartj.120.025902

24 Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A, Sepe PA, Reasasso T, Camporotondo R, Bruno R, Baldanti F, Paolucci S, Pelleghini S, Iotti GA, Moljoi F, Arbustini E. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail 2020; 22: 911-915. DOI: 32275347.

25 John K, Lal A, Mishra A. A review of the presentation and outcome of takotsubo cardiomyopathy in COVID-19. Monaldi Arch Chest Dis 2021; 91. DOI: 10.4081/monaldi.2021.1710

26 Thysgesen K, Alpert JS, Jaffe AS, Chairman BR, Bax JJ, Morrow DA, White HD; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). Circulation 2018; 138: e618-e651. DOI: 10.1161/CIRCULATIONAHA.118.035151

27 Feuchtnier GM, Barbieri F, Luger A, Skalla E, Kountchev J, Widmann G, Plank F. Myocardial injury in COVID-19: The role of coronary computed tomography angiography (CTA). J Cardiovasc Comput Tomogr 2021; 15: e3-e6. DOI: 32474170.

28 Varga Z, Flammer AJ, Steiger P, Haberecker M, Andernatt R, Zinkernagel AS, Mehra MR, Schuapbach RA, Rauschikra F, Moeh G. Endothelial cell infection and endothelitis in COVID-19. Lancet 2020; 395: 1417-1418. DOI: 32325026.

29 Papanikolaou J, Alharthly A, Platogiannis N, Balhamar A, Alqahtani SA, Memish ZA, Karakitsos D. Spontaneous coronary artery dissection in a patient with COVID-19. Coron Artery Dis 2021; 32: 354-355. DOI: 33394695.

30 Aparisi A, Ybarra-Falcón C, García-Granja PE, Uriarrí A, Gutierrez H, Amat-Santos JJ. COVID-19 and spontaneous coronary artery dissection: causality? REC Intern Cardiol 2021; 3: 134-143. DOI: 10.24875/REC.Intern.Cardiolog.2021.03.0202

31 Shojaei F, Habibi Z, Goudarzi S, Firoozabadi FD, Montazerin SM, Najafi H, Khav F, Memomazdeh K, Mir M, Khan F, Jamil U, Janali A, Lee JJ, Chi G. COVID-19: A double threat to takotsubo cardiomyopathy and spontaneous coronary artery dissection? Med Hypotheses 2021; 146: 11040-11041. DOI: 33267999.

32 Yapar Emren Z, Emerin V, Özdemir E, Karagöz U, Nazlı C. Spontaneous right coronary artery dissection in a patient with COVID-19 infection: A case report and review of the literature. Turk Kardiyol Dern Ars 2021; 49: 334-338. DOI: 34106068.

33 Saw J, Aymong E, Sediuk T, Buller CE, Starovoytov A, Ricci D, Robinson S, Vuurmans T, Gao M, Humphries K, Mancini F, Mihr H. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395: 1417-1418. DOI: 32325026.

34 Collet JP, Thiele H, Barbatto E, Barthélémy O, Baudersachs J, Bhat DL, Dendalle P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Roffi M, Rutten GB. Spontaneous coronary artery dissection: association with predisposing arteriopathies and precipitating stressors and cardiovascular outcomes. Circ Cardiovasc Interv 2014; 7: 645-653. DOI: 32524399.

35 Collet JP, Thiele H, Barbatto E, Barthélémy O, Baudersachs J, Bhat DL, Dendalle P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Europace 2021; 2011; 42: 1289-1367. DOI: 32860058.

36 Collet JP, Thiele H, Barbatto E, Barthélémy O, Baudersachs J, Bhat DL, Dendalle P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Europace 2021; 2011; 42: 1289-1367. DOI: 32860058.

37 Collet JP, Thiele H, Barbatto E, Barthélémy O, Baudersachs J, Bhat DL, Dendalle P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Europace 2021; 2011; 42: 1289-1367. DOI: 32860058.

38 Collet JP, Thiele H, Barbatto E, Barthélémy O, Baudersachs J, Bhat DL, Dendalle P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Europace 2021; 2011; 42: 1289-1367. DOI: 32860058.

39 Philip AM, George LJ, John KJ, George AA, Nayar J, Sahu KK, Selvaraj V, Lal A, Mishra AK. A review of the presentation and outcome of left ventricular thrombus in coronavirus disease 2019 infection. J Clin Transl Res 2021; 7: 797-808. DOI: 34983332.

40 John KJ, Nayar J, Mishra AK, Selvaraj V, Khan MS, Lal A. In-hospital clinical complications of COVID-19: a brief overview. Future Virol 2021 [PMID: 34777553 DOI: 10.2217/fvl-2021-0200]

41 Ramasamy C, Mishra AK, John KJ, Lal A. Clinical considerations for critically ill COVID-19 cancer patients: A systematic review. World J Clin Cases 2021; 9: 4841-4852. DOI: 10.12998/wjcc.v9.i28.8441.
